Lumeda is a pioneering brand that is revolutionizing the treatment of lung cancer. Their cutting-edge therapy selectively targets and destroys tumor cells in the lungs, while also stimulating the immune system to recognize and attack any remaining cancer cells. Unlike traditional chemotherapy and radiotherapy, Lumeda's innovative photodynamic therapy (PDT) is highly selective and does not come with toxicities or severe side effects.

Their goal is to provide a more tolerable treatment option for patients with advanced lung cancer and other malignancies. Lumeda's DigiLum™ system enables thoracic surgeons to administer PDT with exceptional precision during standard video-assisted thoracoscopic surgery (VATS) procedures. This breakthrough therapy not only functions as an immune adjuvant in combination with immunotherapy but also showcases promising potential for improving patient responses to treatment.

Committed to advancing the field of oncology, Lumeda collaborates with a diverse team of professionals and leverages the expertise of institutional partners in clinical development and regulatory affairs. They are currently conducting Phase I clinical studies to assess the safety and efficacy of their DigiLum™ system, marking the first clinical evaluation of PDT in combination with immune checkpoint inhibitors for treating NSCLC with pleural disease. With a focus on empowering patients and unlocking the power of immunotherapy, Lumeda is at the forefront of transforming lung cancer treatment